A phase I-II study of niraparib plus temozolomide “1 week on, 1 week off” in patients with recurrent Isocitrate Dehydrogenase (IDH) wild type glioblastoma and IDH mutant gliomas. This evidence concerns the gene IDH3A and central nervous system cancer.